143 related articles for article (PubMed ID: 25439988)
21. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression.
Wilking U; Karlsson E; Skoog L; Hatschek T; Lidbrink E; Elmberger G; Johansson H; Lindström L; Bergh J
Breast Cancer Res Treat; 2011 Jan; 125(2):553-61. PubMed ID: 20628810
[TBL] [Abstract][Full Text] [Related]
22. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
23. Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer.
Roepman P; Horlings HM; Krijgsman O; Kok M; Bueno-de-Mesquita JM; Bender R; Linn SC; Glas AM; van de Vijver MJ
Clin Cancer Res; 2009 Nov; 15(22):7003-11. PubMed ID: 19887485
[TBL] [Abstract][Full Text] [Related]
24. Achieving 95% cross-methodological concordance in HER2 testing: causes and implications of discordant cases.
Grimm EE; Schmidt RA; Swanson PE; Dintzis SM; Allison KH
Am J Clin Pathol; 2010 Aug; 134(2):284-92. PubMed ID: 20660333
[TBL] [Abstract][Full Text] [Related]
25. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.
Rakha EA; Starczynski J; Lee AH; Ellis IO
Histopathology; 2014 Apr; 64(5):609-15. PubMed ID: 24382093
[TBL] [Abstract][Full Text] [Related]
26. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
27. [HER2 epidermal growth factor receptor, tests used to look for its amplification in breast cancer: Principles and limitations].
Eliahiai I; Eljiar M; Chaib S; KHarmoum J; Chraïbi M
Bull Cancer; 2023 Dec; 110(12):1301-1310. PubMed ID: 37858426
[TBL] [Abstract][Full Text] [Related]
28. Assessing the impact of the 2018 American Society of Clinical Oncology/College of American Pathologists recommendations on human epidermal growth factor receptor 2 testing by fluorescence in situ hybridization in breast carcinoma.
Murray C; Flanagan L; D'Arcy C; Gullo G; Quinn CM
Virchows Arch; 2020 Mar; 476(3):367-372. PubMed ID: 31375912
[TBL] [Abstract][Full Text] [Related]
29. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
30. [Re-evaluation of HER2 status in 1 501 invasive breast cancers according to the 2013 American Society of Clinical Oncology/College of American Pathology guidelines].
Zhang H; Zhang S; Wang Y; Li D; Xu L; Liu Q; Duan X; Liu Y; Li T
Zhonghua Bing Li Xue Za Zhi; 2015 Jan; 44(1):42-7. PubMed ID: 25765030
[TBL] [Abstract][Full Text] [Related]
31. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
Gao FF; Dabbs DJ; Cooper KL; Bhargava R
Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
[TBL] [Abstract][Full Text] [Related]
32. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
[TBL] [Abstract][Full Text] [Related]
33. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations.
Gong Y; Sweet W; Duh YJ; Greenfield L; Fang Y; Zhao J; Tarco E; Symmans WF; Isola J; Sneige N
Am J Clin Pathol; 2009 Apr; 131(4):490-7. PubMed ID: 19289584
[TBL] [Abstract][Full Text] [Related]
34. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
35. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity.
Allison KH; Dintzis SM; Schmidt RA
Am J Clin Pathol; 2011 Dec; 136(6):864-71. PubMed ID: 22095371
[TBL] [Abstract][Full Text] [Related]
36. Genetic heterogeneity in HER2 testing may influence therapy eligibility.
Bernasconi B; Chiaravalli AM; Finzi G; Milani K; Tibiletti MG
Breast Cancer Res Treat; 2012 May; 133(1):161-8. PubMed ID: 21901388
[TBL] [Abstract][Full Text] [Related]
37. Change in HER2 status during breast tumor progression.
Niikura N; Ueno NT
Cancer Biomark; 2012-2013; 12(6):251-5. PubMed ID: 23735945
[TBL] [Abstract][Full Text] [Related]
38. Comparison of immunohistochemistry with fluorescence in situ hybridization in determining the human epidermal growth factor receptor 2 status of breast cancer specimens: a multicenter study of 3,149 Chinese patients.
Han X; Shi Y; Ma L; Lyu Z; Yang H; Yao J; Li J; Li B; Qin Y
Chin Med J (Engl); 2014; 127(2):246-53. PubMed ID: 24438611
[TBL] [Abstract][Full Text] [Related]
39. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
40. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
Dolan M; Snover D
Am J Clin Pathol; 2005 May; 123(5):766-70. PubMed ID: 15981817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
